Tag: imlifidsase
Hansa Biopharma announces three-year graft survival of 84% after imlifidase treatment...
Hansa Biopharma has announced three-year follow-up data on graft survival rates in crossmatch positive patients who received imlifidase prior to kidney transplantation. As reported...